Steroid receptor positivity and tumour type are influencing Oncotype DX recurrence score and subsequent treatment delivery in Scotland

Background: Individualised treatment is at the heart of breast cancer care. Genomic assays are now providing evidence to guide adjuvant systemic therapy decision making. The aim of this Pan-Scotland study was to investigate the clinical uptake of Oncotype DX testing and explore the clinical benefit in certain patient sub-groups.